Our Portfolio of Companies

Enabling disruptive scientific changes.

Our unique approach ensures our portfolio companies are creating game changing revolutionary science, actively building collaborative working relationships with our companies to help them grow. As a result, we don’t just invest, we partner to enable disruptive scientific changes helping patients live better lives.

Alpine Immune Sciences

We founded and seed funded Alpine Immune Sciences in 2015 to create modern therapies targeting the immune synapse. The company was created to capitalize on the founders’ unique understanding of immunology, modifying the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. The company closed its Series A funding of $48M in June 2016 (press release). The company became publicly traded in July 2017 (press release) on the NASDAQ under the ticker symbol ‘ALPN’.

Mavupharma logo

Mavupharma

We joined Frazier Healthcare to make a $20M Series A round investment. Mavu is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease. (Press release)

Alpine Biosciences

acquired by

We founded Alpine Biosciences in 2012 to develop ‘protocells’, a unique nanoparticle platform technology licensed from the University of New Mexico and Sandia National Labs. Protocells are designed to enable the targeted delivery of multiple therapeutic agents, including nucleic acids, proteins, peptides, and small molecules. Alpine Biosciences was sold to Cascadian Therapeutics (NASDAQ:CASC) in August of 2014.